Department of Anesthesiology, Tianjin Huanhu Hospital, Tianjin, 300060, China,
Mol Biol Rep. 2013 Dec;40(12):6997-7006. doi: 10.1007/s11033-013-2819-5. Epub 2013 Nov 5.
Tumor necrosis factor (TNF) and the TNF receptor (TNFR) superfamily play very important roles for cell death as well as normal immune regulation. Previous studies have strongly suggested that c-Jun N-terminal kinase (JNK) signaling pathway plays a critical role in ischemic brain injury. The purpose of this investigation was to examine the protective effect of remifentanil preconditioning in cerebral ischemia/reperfusion injury (CIR) and its possible molecular mechanism. Results showed that Remifentanil pretreatment significantly decreased the CD4(+) and increased the CD8(+) in cerebral tissues. Additionally, CD4(+)/CD8(+) in CIR + Remifentanil group was markedly lower than that in CIR group. TNF-α and TNFR1 in CIR + Remifentanil group rats was found to be significant lower than that in CIR group rats. The expression levels of Cyt-c, caspase-3, caspase-9 and pJNK proteins in brain of CIR + Remifentanil group rats were found to significantly decreased compared to CIR group rats. In addition, decreased ROS level indirectly inhibit JNK activation and cell death in CIR rat receiving Remifentanil preconditioning. From current experiment results, at least two signal pathways involve into the process of Remifentanil preconditioning inhibiting cerebral damage induced by ischemia reperfusion. The inhibitory effects of Remifentanil preconditioning on the brain damage are achieved probably through blocking the activation of TNF-α/TNFR1, JNK signal transduction pathways, which implies that Remifentanil preconditioning may be a potential and effective way for prevention of the ischemic/reperfusion injury through the suppression extrinsic apoptotic signal pathway induced by TNF-α/TNFR1, JNK signal pathways. Taken together, this study indicated that regulation of the TNF-α/TNFR1 and JNK signal pathways may provide a new therapy for cerebral damage induced by ischemia and reperfusion.
肿瘤坏死因子(TNF)及其受体(TNFR)超家族在细胞死亡以及正常免疫调节中发挥着非常重要的作用。先前的研究强烈表明,c-Jun N-末端激酶(JNK)信号通路在缺血性脑损伤中起关键作用。本研究旨在探讨瑞芬太尼预处理对脑缺血再灌注损伤(CIR)的保护作用及其可能的分子机制。结果表明,瑞芬太尼预处理可显著降低脑组织中的 CD4+,增加 CD8+。此外,CIR+瑞芬太尼组的 CD4+/CD8+明显低于 CIR 组。CIR+瑞芬太尼组大鼠 TNF-α和 TNFR1 明显低于 CIR 组大鼠。与 CIR 组大鼠相比,CIR+瑞芬太尼组大鼠脑中 Cyt-c、caspase-3、caspase-9 和 pJNK 蛋白的表达水平明显降低。此外,ROS 水平的降低可间接抑制 CIR 大鼠接受瑞芬太尼预处理时 JNK 的激活和细胞死亡。从目前的实验结果来看,至少有两种信号通路参与了瑞芬太尼预处理抑制缺血再灌注引起的脑损伤的过程。瑞芬太尼预处理对脑损伤的抑制作用可能是通过阻断 TNF-α/TNFR1、JNK 信号转导通路的激活来实现的,这表明瑞芬太尼预处理可能通过抑制 TNF-α/TNFR1、JNK 信号通路诱导的细胞外凋亡信号通路,成为一种预防缺血/再灌注损伤的潜在有效方法。综上所述,本研究表明,调节 TNF-α/TNFR1 和 JNK 信号通路可能为缺血再灌注引起的脑损伤提供一种新的治疗方法。